2023-12-01 2024-11-30 false Capium Accounts Production 1.1 12337769 2023-12-01 2024-11-30 12337769 bus:AbridgedAccounts 2023-12-01 2024-11-30 12337769 bus:FRS102 2023-12-01 2024-11-30 12337769 bus:AuditExemptWithAccountantsReport 2023-12-01 2024-11-30 12337769 bus:SmallCompaniesRegimeForAccounts 2023-12-01 2024-11-30 12337769 bus:PrivateLimitedCompanyLtd 2023-12-01 2024-11-30 12337769 2023-12-01 2024-11-30 12337769 2024-11-30 12337769 bus:RegisteredOffice 2023-12-01 2024-11-30 12337769 core:WithinOneYear 2024-11-30 12337769 core:AfterOneYear 2024-11-30 12337769 1 2023-12-01 2024-11-30 12337769 bus:Director1 2023-12-01 2024-11-30 12337769 bus:Director1 2024-11-30 12337769 bus:Director1 2022-12-01 2023-11-30 12337769 2022-12-01 12337769 bus:LeadAgentIfApplicable 2023-12-01 2024-11-30 12337769 2022-12-01 2023-11-30 12337769 2023-11-30 12337769 core:WithinOneYear 2023-11-30 12337769 core:AfterOneYear 2023-11-30 12337769 bus:EntityAccountantsOrAuditors 2022-12-01 2023-11-30 12337769 core:CostValuation core:Non-currentFinancialInstruments 2024-11-30 12337769 core:CostValuation core:Non-currentFinancialInstruments 2023-11-30 12337769 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2024-11-30 12337769 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2024-11-30 12337769 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2024-11-30 12337769 core:Non-currentFinancialInstruments 2024-11-30 12337769 core:Non-currentFinancialInstruments 2023-11-30 12337769 core:ShareCapital 2024-11-30 12337769 core:ShareCapital 2023-11-30 12337769 core:RetainedEarningsAccumulatedLosses 2024-11-30 12337769 core:RetainedEarningsAccumulatedLosses 2023-11-30 12337769 dpl:Item1 2023-12-01 12337769 dpl:Item1 2024-11-30 12337769 dpl:Item1 2022-12-01 12337769 dpl:Item1 2023-11-30 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 12337769


 

 

 

MIDPHARM LTD



Abridged Accounts
 


Period of accounts

Start date: 01 December 2023

End date: 30 November 2024
 
 
Notes
 
2024
£
  2023
£
Current assets      
Cash at bank and in hand 33,837    44,790 
Creditors: amount falling due within one year (3,122)   (11,334)
Net current assets 30,715    33,456 
 
Total assets less current liabilities 30,715    33,456 
Net assets 30,715    33,456 
 

Capital and reserves
     
Called up share capital 100    100 
Profit and loss account 30,615    33,356 
Shareholders' funds 30,715    33,456 
 


For the year ended 30 November 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
  2. The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with section 444(2A).
The financial statements were approved by the director on 09 June 2025 and were signed by:


-------------------------------
Mohammed Azim
Director
1
General Information
MIDPHARM LTD is a private company, limited by shares, registered in , registration number 12337769, registration address 25 Oxford Close, Birmingham, B8 2JE.

The presentation currency is £ sterling.
1.

Accounting policies

Significant accounting policies
Statement of compliance
These financial statements have been prepared in compliance with FRS 102 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.
Basis of preparation
The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies.
The financial statements are prepared in sterling which is the functional currency of the company.
Turnover
Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.
Taxation
Taxation represents the sum of tax currently payable and deferred tax. Tax is recognised in the statement of income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves.
The company’s liability for current tax is calculated using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Current and deferred tax assets and liabilities are not discounted
2.

Average number of employees

Average number of employees during the year was 1 (2023 : 1).
2